| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6167173 | Urology | 2015 | 7 Pages |
Abstract
Substantial clinicopathologic stage discrepancies occurred even in patients seemingly ideal for BPT, which may provide insight into BPT failures. Furthermore, substantial survival discrepancies existed for BPT-eligible and BPT-ineligible patients, underscoring the heterogeneity of cT2 disease. In the absence of randomized trials, comparisons between RC and BPT must factor in selection bias.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Eugene J. Pietzak, Matthew E. Sterling, Zachary L. Smith, S. Bruce Malkowicz, Thomas J. Guzzo,